EN DE
Watch Ingevity Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ingevity Corp (NGVT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Ingevity Corp stock $96.19, price $60.12, upside +60.0%, quality 66 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials US

IC Ingevity Corp logo Some data Nov 7, 2026

Ingevity Corp

NGVT · US
Undervalued, in an uptrend

The stock costs 38% less than our calculation considers fair.

Fair value $96.19 · Strongly undervalued
Quality 66/100
Generates free cash flow
Upbeat coverage
Mixed Growth (revenue 5y +8.3 %/yr in USD)
Thin margins · 5.3% net margin (TTM) · excl. goodwill write-downs +21.5%
Mixed vs. peers (6/13)
Moderate moat 59/100 · thin data
Insiders sold $1.8M (6M)
Some data
Revenue last quarter 8% below a year ago.
High debt
⟳ Cyclical
Watch Ingevity Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$90.75 $29.88 Fair Value $96.19 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $29.88 – $90.75 · fair‑value band $60.24 – $129.25 · the $60.12 price screens below the $96.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Ingevity in your weekly email

Every Wednesday you see whether Ingevity is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America.

Show moreShow less

It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.

The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats.

This segment also produces other activated carbon products for food, water, beverage, and chemical purification applications. The Performance Chemicals segment consists of road technologies and industrial specialties.

This segment's products are used in pavement construction, pavement preservation, pavement reconstruction and recycling, road markings, agrochemical dispersants, lubricants, certain adhesives, rubber, and other industrial uses.

The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices.

It serves automotive parts manufacturers through sales representatives, third-party sales representatives, and distributors. The company was formerly known as WestRock Company, Specialty Chemicals Business and changed its name to Ingevity Corporation in September 2015.

Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.

Stock analysis

Ingevity Corp (NGVT) currently trades at $60.12, while our model-based Fair Value estimate is $96.19, implying the stock looks roughly 38% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $72.94 per share, and 6 of the 12 models we run sit above the $60.12 price.

Bear case: the Earnings-Based group reads lowest at $37.05, and 6 of the 12 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $60.24 (bear) to $129.25 (bull), the price of $60.12 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Basic Materials sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Ingevity Corp reported revenue of $1.2B in FY2025 versus $1.4B in FY2021, a compound −4.3%/yr. Reported net income was −$167M in FY2025.

Key figures

Market cap $2.1B Mid · P/E ratio 57.3 · P/S ratio 1.83 · EPS (TTM) $1.05 · Net margin −14.3% · Return on equity 35.3% · Return on assets (EBIT) 12.7% (5-year average) · Operating margin 28.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 60%, NGVT screens cheaper than that median.

Fair Value models

Bear $60.24 Fair Value $96.19 Bull $129.25
Price $60.12 · Upside +60.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.9004 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $57.24 $85.67 $137.91 79
Growth DCF $60.40 $87.76 $133.92 78
5Y EBITDA Exit $45.58 $76.88 $119.23 74
All 12 models by family
DCF Models
FCF DCF $57.24 $85.67 $137.91 79
5Y Revenue Exit $24.16 $40.21 $64.00 71
5Y EBITDA Exit $45.58 $76.88 $119.23 74
10Y Revenue Exit $36.39 $50.55 $65.26 68
10Y EBITDA Exit $49.76 $72.94 $97.79 69
Earnings-Based
EPV $28.11 $37.05 $44.67 74
Multiples
EV/EBIT $46.12 $72.78 $99.44 64
EV/EBITDA $46.47 $73.26 $100.04 66
EV/Revenue $1.79 $17.07 $32.35 47
Growth DCF
Growth DCF $60.40 $87.76 $133.92 78
Rev-Margin DCF $24.16 $42.39 $66.19 71
Economic Profit
ROIC Compounder $28.53 $39.33 $50.40 72

The fair value above starts from this blend and is adjusted for a cyclical trough year.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 66/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 90
Do the profits arrive as real cash?
Financial strength 20
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 45
Distance to the 52-week high, does not count
New shares 94
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.8M and none bought.

  • SaleDavid H LiPresident & CEO, Director2× since Aug 12, 2026: 20,092 shares, avg. $75.97$1.5MAug 18, 202610b5-1 plan
  • SaleRyan C. FisherSVP, Gen. Counsel & Secretary2,709 shares at $73.72$199,698Aug 3, 2026
  • SaleTerrance M DyerSVP, Chief HR Officer496 shares at $68.49$33,971May 28, 2026

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−1.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −1.5% a year for the price and −3.4% for the forecasts.
Forecast 2026 (sales)−1.6%
Forecast 2027 (sales)−1.6%
Projected 2028 (sales)−1.2%
Projected 2029 (sales)−0.7%
Projected 2030 (sales)−0.3%

Watch NGVT, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: Sharpened focus on activated carbon and pavement solutions after the divestiture forms the main strength, while negative profitability and elevated leverage remain the central weakness.
Main risk: The tighter portfolio heightens exposure to demand swings in the remaining pavement technologies and activated carbon markets, directly pressuring cycle returns.
Ingevity just closed the sale of its North Charleston crude tall oil refinery and most of the related Industrial Specialties product line. The step exits lower-margin CTO activities while retaining pavement technologies and lignin products, sharpening focus on activated carbon and pavement solutions. Our models currently see the shares as undervalued. Will the tighter portfolio lift returns through the cycle or heighten exposure to swings in the remaining core markets?
Join the discussion →

Compare Ingevity Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 728 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside +60.0% · Top 25%
Profitability
Return on equity (12 months) 35.3% · Top 25%
Return on assets −10.1% · Bottom 25%
Net margin (12 months) 5.3% · Below median
Operating margin (12 months) 28.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −8.4% · Bottom 25%
Balance sheet
Debt / equity 39.10× · Highest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (12 months) 57.3× · Priciest 25%
P/S (12 months) 1.89× · Pricier than median
Price / free cash flow (fiscal year) 7.8× · Cheapest 25%
EV/EBITDA 8.7× · Cheaper than median
PEG 2.41× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 67
PAST (return on equity)100 · sector 27
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nan Ya Plastics Corporation 1303 263.00 TWD 420.80 TWD +60% vs NGVT
Wanhua Chemical Group 600309 ¥72.65 ¥68.03 −6% vs NGVT
Linde plc LIN $515.25 $446.62 −13% vs NGVT
PPG Industries, Inc PPG $122.38 $77.68 −37% vs NGVT
DSM-Firmenich AG DSFIR CHF 100.50 CHF 57.70 −43% vs NGVT
The Sherwin-Williams Company SHW $344.10 $146.37 −57% vs NGVT
Givaudan SA GIVN CHF 4,054 CHF 1,554 −62% vs NGVT
EMS-CHEMIE HOLDING AG EMSN CHF 848.50 CHF 284.63 −66% vs NGVT
Ecolab Inc ECL $300.68 $96.56 −68% vs NGVT
Air Products and Chemicals, Inc APD $304.84 $75.33 −75% vs NGVT

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ingevity Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ingevity Corp Fair Value". https://www.fairvalue-calculator.com/stock/NGVT

Frequently asked questions

Is Ingevity Corp (NGVT) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $96.19 versus a price of $60.12, about +60% upside (undervalued).
What is the fair value of NGVT?
Our model-based fair value for Ingevity Corp is $96.19 (as of Nov 7, 2026), built from audited fundamentals. The current price: $60.12.
What is the quality score of NGVT?
Ingevity Corp has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ingevity Corp (NGVT)?
Our model-based price target is the fair value of $96.19 (as of Nov 7, 2026) from 12 valuation models. Cautious scenario $60.24, optimistic scenario $129.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Ingevity Corp stock forecast for 2026?
Our models put fair value at $96.19, about +60% upside versus a price of $60.12 (undervalued). Cautious scenario $60.24, optimistic scenario $129.25. The calculation is refreshed regularly with new filings.
What is the revenue of Ingevity Corp (NGVT)?
Ingevity Corp reported trailing-twelve-month revenue of about $1.1B (latest available figure, as of Nov 7, 2026).
What growth is priced into Ingevity Corp (NGVT)?
For today's price to be fair in a discounted-cash-flow model, Ingevity Corp would have to grow free cash flow by +0.8 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.8 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of NGVT use?
Our models discount Ingevity Corp at 10.0 %: a base by market capitalisation (mid), damped by beta 1.11, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ingevity Corp that is +0.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Ingevity Corp (NGVT) delivered so far?
Over the past 5 years revenue at Ingevity Corp grew -0.8 % a year. The price currently implies free-cash-flow growth of +0.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ingevity Corp (NGVT) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Ingevity Corp (+0.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ingevity Corp (NGVT)?
The free-cash-flow yield on the price is 12.78 %: that much free cash flow Ingevity Corp produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ingevity Corp (NGVT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ingevity Corp it is $96.19 per share (as of Nov 7, 2026), against a price of $60.12. It is the blended result of 12 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is Ingevity Corp stock overvalued or undervalued in 2026?
As of Nov 7, 2026, NGVT trades below its calculated fair value: price $60.12, fair value $96.19, a gap of about +60% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NGVT?
No. The price is what the market pays today ($60.12); the fair value is what the company's own numbers justify ($96.19). For Ingevity Corp the two are $36.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ingevity Corp worth?
The market values Ingevity Corp at about $2.1B (market capitalisation, as of Nov 7, 2026). Per share that is $60.12; our models calculate a fair value of $96.19 per share.
What do the bullish and bearish scenarios say about NGVT?
Our models span a range for Ingevity Corp: cautious scenario $60.24, base $96.19, optimistic $129.25 per share (as of Nov 7, 2026, price $60.12). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NGVT?
Ingevity Corp trades at a price-to-earnings ratio of 57.3 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $96.19 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2016 to 2022), reported earnings: 21.1. Other multiples: PEG 2.4, P/S 1.9, EV/EBITDA 8.7.
What is the PEG ratio of NGVT?
The PEG ratio of Ingevity Corp is 2.41 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Ingevity Corp (NGVT)?
Balance-sheet figures for Ingevity Corp (as of Nov 7, 2026): return on equity 35.3%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is NGVT from its 52-week high?
Ingevity Corp trades at $60.12, about 23% below its 52-week high of $77.87 and 30% above the low of $46.20 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $96.19 is for.
Which stocks are comparable to Ingevity Corp?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ingevity Corp stock attractive at the current price?
The data as of Nov 7, 2026: price $60.12, calculated fair value $96.19 (+60%), Quality Score 66/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NGVT calculated?
We run Ingevity Corp through 12 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $96.19 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ingevity Corp currently trades 38% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ingevity Corp (NGVT)?
The closing price on Nov 6, 2026 was $60.12. Our model-based fair value is $96.19, about +60% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ingevity Corp right now?
Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($60.24 to $129.25) leaves room in how you read the outcome.

Key figures of Ingevity Corp

How large is the market capitalisation of Ingevity Corp (NGVT)?
The market capitalisation of Ingevity Corp is $2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ingevity Corp (NGVT)?
The price-to-sales ratio of Ingevity Corp is 1.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ingevity Corp (NGVT)?
Earnings per share at Ingevity Corp are $1.05 (price ÷ EPS = P/E 57.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ingevity Corp (NGVT)?
The net margin of Ingevity Corp is −14.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ingevity Corp (NGVT)?
The return on equity (ROE) of Ingevity Corp is 35.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ingevity Corp (NGVT)?
On an EBIT basis the return on assets of Ingevity Corp is 12.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ingevity Corp (NGVT)?
The operating margin of Ingevity Corp is 28.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ingevity Corp (NGVT)?
Revenue at Ingevity Corp is growing −8.4% versus a year earlier (3y avg −11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ingevity Corp (NGVT)?
Earnings per share at Ingevity Corp are growing +20.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Ingevity Corp (NGVT) carry?
The net debt of Ingevity Corp is $1.2B (fiscal year 2025, ≈ 4.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ingevity Corp in the live analysis

One click puts Ingevity Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.